Base case

Low value

High value

Ref.

Baseline CKD

CKD stage 2

0.105

0.08

0.13

[14]

CKD stage 3a

0.309

0.25

0.37

[14]

CKD stage 3b

0.441

0.35

0.53

[14]

CKD stage 4

0.145

0.12

0.17

[14]

Overall survival

Dapagliflozin

OS Weibull c

1.5893

1.2714

1.9072

[14]

OS Weibull k

0.0002

0.0001

0.0002

[14]

SOC

OS Weibull c

1.5

1.2000

1.8000

[14]

OS Weibull k

0.002

0.0002

0.0003

[14]

Rate of adverse events

Dapagliflozin

Base case

Low value

High value

Ref.

hHF

0.017

0.01

0.02

[10]

AKI

0.059

0.0472

0.0708

[14]

GI

0.009

0.01

0.01

[16]

UTI

0.015

0.01

0.02

[16]

Major hypoglycemia

0.007

0.0056

0.0084

[14]

SOC

hHF

0.033

0.026

0.04

[10]

AKI

0.042

0.0336

0.0504

[14]

GI

0.001

0.001

0.001

[16]

UTI

0.016

0.013

0.019

[16]

Major hypoglycemia

0.013

0.0104

0.0156

[14]

Utilities

CKD 1

0.85

0.68

1.02

[18]

CKD 2

0.85

0.68

1.02

[18]

CKD 3a

0.8

0.64

0.96

[18]

CKD 3b

0.8

0.64

0.96

[18]

CKD 4

0.566

0.4528

0.6792

[19]

CKD 5

0.467

0.3736

0.5604

[19]

Dialysis

0.126

0.1008

0.1512

[19]

Renal transplant

0.83

0.66

1

[20]

Disutility of AE

hHF

0.1

0.08

0.12

[21]

AKI

0.05

0.04

0.06

[22]

GI

0.038

0.03

0.05

[22]

UTI

0.025

0.02

0.03

[22]

Severe hypoglycemia

0.01

0.008

0.012

[23]